T. Rowe Price Associates
NUTX

T. Rowe Price Associates’s Nutex Health NUTX Stock Holding History

T. Rowe Price Associates’s Portfolio NUTX Stock Details NUTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$347K Buy
3,648
+1,588
+77% +$195K ﹤0.01% 2616
2025
Q4 		$340K Buy
+2,060
New +$273K ﹤0.01% 2581
2025
Q3 		– Sell
-1,717
Closed -$214K – 3093
2025
Q2 		$214K Buy
+1,717
New +$222K ﹤0.01% 2683
2023
Q2 		– Sell
-299
Closed -$46K – 2922
2023
Q1 		$46K Buy
299
+4
+1% +$810 ﹤0.01% 2799
2022
Q4 		$84K Buy
+295
New +$56.7K ﹤0.01% 2748

Other funds holding NUTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PP
Pertento Partners London, United Kingdom $1.37B AUM 36.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WC
Winmill & Co Rochester, New York $347M AUM 37.48% 1-Year Est. Return

T. Rowe Price Associates's NUTX Position: Q1 2026 in Review

T. Rowe Price Associates increased its Nutex Health (NUTX) stake by 77% in Q1 2026, buying an estimated $195K and bringing the position to 3,648 shares worth $347K. The position accounts for ﹤0.01% of the portfolio, ranked #2616.

T. Rowe Price Associates first reported a position in NUTX in Q4 2022 and has held it in 5 quarters since. 129 funds tracked by Wall St. Rank hold NUTX as of Q1 2026.

  • T. Rowe Price Associates held 3,648 shares of Nutex Health worth $347K as of Q1 2026.
  • T. Rowe Price Associates bought 1,588 Nutex Health shares in Q1 2026, an estimated $195K.
  • Nutex Health made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #2616 holding.
  • T. Rowe Price Associates first reported a position in Nutex Health in Q4 2022 and has held it in 5 quarters since.
  • 129 funds tracked by Wall St. Rank held Nutex Health as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.